US releases guidance on REMS negotiation

Draft US guidance documents on developing a shared-system risk evaluation and mitigation strategy (REMS) and waivers for single shared-system REMS will “help generic drug makers get their products through the development and approval processes efficiently, while maintaining the safety controls”, according to US Food and Drug Administration (FDA) Commissioner Scott Gottlieb.